Peptides · Peptide comparison
Orforglipron vs Retatrutide
First oral non-peptide GLP-1 receptor agonist for diabetes and obesity
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Weight Management
Blood Sugar Control
Cardiovascular Health
Weight Loss Power
Metabolic Health
Appetite Control
Technical data
Compound specifications
Orforglipron
- Molecular formula
- C48H48F2N10O5
- Molecular weight
- 883.0 Da
- Half-life
- About 29–49 hours (elimination half-life after an oral dose)
- Bioavailability
- 77% absolute oral bioavailability (0.8 mg dose); no clinically relevant food effect
- CAS number
- 2212020-52-3
Retatrutide
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Half-life
- ~6 days (allows once-weekly dosing)
- Bioavailability
- High via subcutaneous injection
- CAS number
- 2381089-83-2
Protocols
Dosing compared
Orforglipron
Oral
- At least 30 days0.8 mg once dailyOnce daily, with or without food · At least 30 daysLabel starting dose. After at least 30 days, increase to 2.5 mg once daily, then after at least 30 more days to 5.5 mg once daily; gradual escalation reduces gastrointestinal reactions [7]. Tablets are swallowed whole, one per day [7].
- Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg5.5 mg once dailyOnce daily, with or without food · Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mgFirst maintenance-level dose on the label's escalation [7]. In the phase 3 trial without diabetes, 5.5 mg produced 7.4% average weight loss at 72 weeks against 2.1% on placebo [7].
- Ongoing; each step after at least 30 days on the previous dose9–17.2 mg once dailyOnce daily, with or without food · Ongoing; each step after at least 30 days on the previous doseOptional further steps of 9 mg, 14.5 mg and 17.2 mg based on response and tolerability; 17.2 mg is the maximum, and 9 mg is the maximum alongside a strong CYP3A4 inhibitor [7]. 17.2 mg produced 11.1% average weight loss at 72 weeks against 2.1% on placebo [7].
Retatrutide
Subcutaneous
- Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
- Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
- Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Applications
Best suited for
Orforglipron
- Oral GLP-1 receptor agonism without injection burden
- Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Weight management in obesity with or without type 2 diabetes
- Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Glycemic control in type 2 diabetes as add-on to metformin
- Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Cardiovascular risk reduction through weight loss and metabolic improvements
- Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
- Significant Obesity Management
- If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
- Type 2 Diabetes with Obesity
- Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
- Metabolic Syndrome Warriors
- If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
- Fatty Liver Disease (MASLD)
- Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety profile
Side effects
Orforglipron
Common
- Nausea
- Constipation
- Diarrhea
- Vomiting
Uncommon
- Heart Rate Increase
Serious
- Pancreatitis Risk
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research status
Safety & evidence
Orforglipron
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use — as FOUNDAYO (orforglipron) tablets, on 1 April 2026, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. Not approved for type 2 diabetes.
- Safety overview
- Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management. [7][8] Its label carries a boxed warning on thyroid C-cell tumours seen with GLP-1 receptor agonists in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. [7] In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent during dose escalation; 8% stopped treatment for adverse reactions against 3% on placebo. [7] Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycaemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration under anaesthesia. [7]
Contraindications
- Personal or family history of medullary thyroid carcinoma (boxed-warning contraindication) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7]
- Known hypersensitivity to orforglipron or excipients [7]
- History of pancreatitis (use with caution)
Retatrutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Decision guide
Which is right for you?
Orforglipron
Choose Orforglipron if…
- Oral GLP-1 receptor agonism without injection burden
- Weight management in obesity with or without type 2 diabetes
- Glycemic control in type 2 diabetes as add-on to metformin
- Cardiovascular risk reduction through weight loss and metabolic improvements
Retatrutide
Choose Retatrutide if…
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization